急性冠脉综合征患者CABG术前氯吡格雷使用与结局
该回顾性研究纳入5543例ACS行单纯CABG患者,820例(14.8%)术前5天内继续氯吡格雷。倾向评分逆概率加权后,术前5天内氯吡格雷与主要复合终点、卒中、大出血和输血风险显著增加相关。
要点
- ACS行CABG前5天内使用氯吡格雷增加主要心脑血管事件风险。
- 术前5天内氯吡格雷与卒中、大出血及输血风险显著增加相关。
- 年龄>65岁患者术前氯吡格雷对主要结局和大出血影响更大。
核心结论
- ACS行CABG患者术前5天内使用氯吡格雷与主要心脑血管事件及出血并发症风险增加相关。
研究设计与样本
- 单中心回顾性研究,连续纳入ACS行单纯CABG患者5543例,采用倾向评分逆概率加权进行风险校正。
主要发现
- 820例(14.8%)患者在CABG前5天内继续使用氯吡格雷。
- 校正后,术前5天内氯吡格雷与主要复合终点风险增加相关(OR 1.63;95%CI 1.16-2.29;P=.005)。
- 术前5天内氯吡格雷与卒中风险增加相关(OR 3.13;95%CI 1.82-5.39;P<.001)。
- 术前5天内氯吡格雷与大出血风险增加相关(OR 2.01;95%CI 1.56-2.58;P<.001)。
- 术前5天内氯吡格雷与输血风险增加相关(OR 2.05;95%CI 1.82-2.30;P<.001)。
临床怎么用
- ACS行CABG术前应评估氯吡格雷停药时机,权衡出血与缺血风险。
局限性
- 单中心回顾性设计可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal preoperative antiplatelet strategy for patients with acute coronary syndrome (ACS) requiring surgical revascularization remains unclear because of competing risks of bleeding and ischemic events. We evaluated the effect of clopidogrel within 5 days before coronary artery bypass grafting (CABG) on outcomes in patients with ACS. METHODS: Consecutive patients with ACS who underwent isolated CABG at a single center were included in this retrospective study. The primary outcome was a composite of death, myocardial infarction, and stroke within 30 days after surgery. Secondary outcomes were CABG-related major bleeding and perioperative transfusion. Inverse probability weighting using propensity score was performed to evaluate the risk-adjusted effect of preoperative clopidogrel on outcomes. RESULTS: Of 5543 patients with ACS, 820 (14.8%) patients continued clopidogrel within 5 days before CABG. After adjustment for differences in baseline factors, clopidogrel use ≤5 days before CABG was associated with significantly increased odds of the primary composite outcome (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.29; P = .005), stroke (OR, 3.13; 95% CI, 1.82-5.39; P < .001), major bleeding (OR, 2.01; 95% CI, 1.56-2.58; P < .001), and transfusion (OR, 2.05; 95% CI, 1.82-2.30; P < .001). The effects of preoperative clopidogrel use ≤5 days on primary outcome and major bleeding were greater in patients older than 65 years. CONCLUSIONS: Among patients with ACS undergoing CABG, clopidogrel therapy within 5 days before surgery was associated with increased odds of major cardiac and cerebrovascular events and bleeding complications than discontinuing clopidogrel for >5 days.
引用
- Qu J, Zhang D, Zhang H, et al. Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2020. PMID: 32444184. doi:10.1016/j.jtcvs.2020.03.118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。